Simultaneous Presentation of Post-Transplant Lymphoproliferative Disorder (PTLD) and Acute Cellular Rejection (ACR) in a Liver Transplant Recipient: A Therapeutic Conundrum.
Ankit Mishra, Matthew Kubina, Dhiraj K Peddu, Benjamin L Viglianti, Anamarija M Perry, Priya Kathuria, Hellan Kwon, Shannon A Carty, Patricia Bloom
{"title":"Simultaneous Presentation of Post-Transplant Lymphoproliferative Disorder (PTLD) and Acute Cellular Rejection (ACR) in a Liver Transplant Recipient: A Therapeutic Conundrum.","authors":"Ankit Mishra, Matthew Kubina, Dhiraj K Peddu, Benjamin L Viglianti, Anamarija M Perry, Priya Kathuria, Hellan Kwon, Shannon A Carty, Patricia Bloom","doi":"10.1155/crgm/1627234","DOIUrl":null,"url":null,"abstract":"<p><p>We report a 64-year-old liver transplant recipient who developed early nondestructive post-transplant lymphoproliferative disorder (PTLD) and severe acute cellular rejection (ACR) concurrently. Hepatic lymphadenopathy led to a liver biopsy demonstrating early PTLD. Immunosuppression (IS) was reduced for early PTLD, which led to acute liver injury requiring high-dose steroids. However, subsequent augmentation in immunosuppression for ACR led to progression of PTLD, requiring rituximab treatment. This case highlights the complexity of managing conflicting liver transplant complications and underscores the importance of a multidisciplinary approach. In our case, prioritizing the treatment of rejection preserved the allograft function. Long-term follow-up showed complete resolution of both rejection and PTLD.</p>","PeriodicalId":45645,"journal":{"name":"Case Reports in Gastrointestinal Medicine","volume":"2025 ","pages":"1627234"},"PeriodicalIF":0.6000,"publicationDate":"2025-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12588761/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Case Reports in Gastrointestinal Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/crgm/1627234","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
We report a 64-year-old liver transplant recipient who developed early nondestructive post-transplant lymphoproliferative disorder (PTLD) and severe acute cellular rejection (ACR) concurrently. Hepatic lymphadenopathy led to a liver biopsy demonstrating early PTLD. Immunosuppression (IS) was reduced for early PTLD, which led to acute liver injury requiring high-dose steroids. However, subsequent augmentation in immunosuppression for ACR led to progression of PTLD, requiring rituximab treatment. This case highlights the complexity of managing conflicting liver transplant complications and underscores the importance of a multidisciplinary approach. In our case, prioritizing the treatment of rejection preserved the allograft function. Long-term follow-up showed complete resolution of both rejection and PTLD.